来曲唑诱导冻胚移植可降低多囊卵巢综合征患者妊娠期高血压疾病风险
该回顾性队列纳入2010—2018年单中心2427例多囊卵巢综合征冻胚移植女性,比较人工周期与来曲唑诱导周期。校正混杂因素后,来曲唑组单胎和双胎妊娠的妊娠期高血压疾病风险均低于人工周期组,其余围产结局相当。
要点
- 来曲唑诱导周期单胎妊娠期高血压疾病风险低于人工周期(aOR 0.63,95%CI 0.40-0.98)。
- 双胎妊娠中来曲唑组妊娠期高血压疾病风险亦降低(aOR 0.52,95%CI 0.30-0.87)。
- 来曲唑组单胎剖宫产率更低(aOR 0.63,95%CI 0.50-0.78),双胎无差异。
核心结论
- 多囊卵巢综合征患者冻胚移植时,来曲唑行子宫内膜准备较人工周期与更低的妊娠期高血压疾病风险相关。
- 采用促使黄体形成的生理性内膜准备方案,可能减轻冻胚移植相关的妊娠期高血压疾病风险升高。
研究设计与样本
- 回顾性队列研究,纳入2010至2018年单家三级医疗中心行人工冻胚周期或来曲唑刺激冻胚周期的多囊卵巢综合征女性。
- 最终分析2427例,其中人工周期1168例,来曲唑治疗1259例;来曲唑组中25%单用来曲唑、75%来曲唑联合促性腺激素。
- 主要结局为妊娠期高血压疾病发生率,采用多因素logistic回归校正相关混杂因素。
主要发现
- 校正母体特征与治疗变量后,单胎及双胎中妊娠期糖尿病、胎盘异常及未足月胎膜早破组间无显著差异。
- 单胎及双胎中早产、围产儿死亡及出生体重结局组间均相当。
- 来曲唑组单胎妊娠期高血压疾病风险低于人工周期组(aOR 0.63,95%CI 0.40-0.98)。
- 来曲唑组双胎妊娠期高血压疾病风险低于人工周期组(aOR 0.52,95%CI 0.30-0.87)。
- 单胎剖宫产率来曲唑组显著更低(aOR 0.63,95%CI 0.50-0.78),双胎无显著差异(aOR 1.20,95%CI 0.65-2.23)。
关键数值与推荐
- 主要结局妊娠期高血压疾病:单胎aOR 0.63(95%CI 0.40-0.98),双胎aOR 0.52(95%CI 0.30-0.87),均以来曲唑组对比人工周期组。
- 剖宫产率:单胎aOR 0.63(95%CI 0.50-0.78),双胎aOR 1.20(95%CI 0.65-2.23)。
临床怎么用
- 对多囊卵巢综合征行冻胚移植者,可考虑来曲唑诱导这一促使黄体形成的生理性内膜准备方案以降低妊娠期高血压疾病风险。
- 决策时仍需结合患者排卵状态与既往周期情况个体化选择内膜准备方案。
局限性
- 为单中心回顾性队列研究,可能存在残余混杂。
- 来曲唑组包含单用及联合促性腺激素两种方案,未单独分层分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Observational retrospective data suggest that an artificial cycle frozen embryo transfer may be associated with a higher risk of hypertensive disorder of pregnancy than a natural cycle frozen embryo transfer among women with regular ovulatory cycles. The corpus luteum, which is not present in the artificial frozen cycles, is at least partly responsible for this poor obstetrical outcome. However, an artificial cycle is the most frequently used regimen for women with polycystic ovary syndrome undergoing frozen embryo transfer. Whether the risk of hypertensive disorder of pregnancy could be mitigated by employing physiological frozen embryo transfer protocols that lead to the development of a corpus luteum in patients with polycystic ovary syndrome remains unknown. OBJECTIVE: This study aimed to investigate the impact of letrozole use during frozen embryo transfer cycles on obstetrical and perinatal outcomes of singleton and twin pregnancies compared with artificial frozen cycles among women with polycystic ovary syndrome. STUDY DESIGN: This retrospective cohort study involved women with polycystic ovary syndrome who had undergone artificial frozen cycles or letrozole-stimulated frozen cycles during the period from 2010 to 2018 at a tertiary care center. The primary outcome was the incidence of hypertensive disorder of pregnancy. A multivariable logistic regression analysis was performed to control for the relevant confounders. RESULTS: A total of 2427 women with polycystic ovary syndrome were included in the final analysis. Of these women, 1168 underwent artificial cycles and 1259 underwent letrozole treatment, of which 25% of women treated with letrozole alone and 75% of women receiving letrozole combined with gonadotropins. After controlling for maternal characteristics and treatment variables, no significant difference was noticed regarding gestational diabetes mellitus, abnormal placentation, and preterm premature rupture of membranes between groups in both singleton and twin pregnancies. For birth outcomes, the prevalence rates of preterm birth, perinatal death, and birthweight outcomes were all comparable between groups in both singletons and twins. However, singleton pregnancies resulting from letrozole-stimulated cycles had a lower risk of hypertensive disorder of pregnancy than those conceived by artificial cycles (adjusted odds ratio, 0.63; 95% confidence interval, 0.40-0.98). Furthermore, a decreased risk of hypertensive disorder of pregnancy was seen among women with twin deliveries resulting from letrozole-stimulated cycles vs artificial cycles (adjusted odds ratio, 0.52; 95% confidence interval, 0.30-0.87). In addition, the cesarean delivery rate was significantly lower for singletons but not for twins in the letrozole group compared with pregnancies from the artificial cycle group (adjusted odds ratio, 0.63; 95% confidence interval, 0.50-0.78, and adjusted odds ratio, 1.20; 95% confidence interval, 0.65-2.23, respectively). CONCLUSION: In women with polycystic ovary syndrome undergoing frozen embryo transfer, letrozole use for endometrial preparation was associated with a lower risk of hypertensive disorder of pregnancy than artificial cycles for endometrial preparation. Our findings provided a foundation that the increased risk of hypertensive disorder of pregnancy associated with frozen embryo transfer might be mitigated by utilizing physiological endometrial preparation protocols that lead to the development of a corpus luteum, such as a mild ovarian stimulation cycle for oligo- or anovulatory women.
引用
- Zhang J, Wei M, Bian X, et al. Letrozole-induced frozen embryo transfer cycles are associated with a lower risk of hypertensive disorders of pregnancy among women with polycystic ovary syndrome. Am J Obstet Gynecol. 2021. PMID: 33529574. doi:10.1016/j.ajog.2021.01.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。